Less Ads, More Data, More Tools Register for FREE

Pin to quick picksDr. Martens Regulatory News (DOCS)

Share Price Information for Dr. Martens (DOCS)

Share Price is delayed by 15 minutes
Get Live Data
70.00    -2.30 (-3.18%)
Bid:
71.00
Ask:
71.30
Spread: 0.30 (0.423%)
Market Cap: £669.96m
DOCS Live PriceLast checked at - London Stock Exchange

Intraday Dr. Martens Share Chart

CFO retirement

14 Apr 2023 07:01

RNS Number : 1908W
Dr. Martens PLC
14 April 2023
 

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION

 

14 April 2023

Dr. Martens plc

("the Company")

 

CFO retirement

 

Dr. Martens Plc today announces that, with agreement of the Board, Jon Mortimore has decided to retire from his role as Chief Financial Officer (CFO) of the Company. Jon will continue in his role until a successor is in place to ensure a smooth transfer of responsibilities.

The Company is commencing an external search for Jon's successor.

Jon joined the company in April 2016. During his seven years at Dr. Martens, Jon has been instrumental in delivering the Company's transition from a family-run company to a listed PLC, overseeing revenue growth from £230m to £1bn, as well as playing an integral role in the Company's initial public offering (IPO) in January 2021.

Paul Mason, Dr. Martens Chair said "On behalf of the Board, I would like to thank Jon for his central role in driving the strong growth and strategic development of Dr. Martens over the last seven years. His knowledge of the business and understanding of the Company's value drivers have played a key part in helping develop the business during this period. We also want to thank him for his careful stewardship of the finance function, in particular during the pandemic period, which is testament to his dedication and exceptional hard work. We wish him well in his retirement."

Jon Mortimore, CFO added "I am proud of the progress that Dr. Martens has achieved during my time as CFO since 2016 and I look forward to seeing further growth and success in the years to come. This is a great company with an incredible brand and passionate people, and I believe it has a very exciting long-term future ahead of it. I will be retiring once my successor is in place but until then, I will continue to support Dr. Martens in my role as CFO."

 

Enquiries

Investors and analysts

Mark Blythman, Interim Director of Investor Relations Mark.Blythman@drmartens.com +44 7570 871207

Beth Callum, Senior Investor Relations Analyst Beth.callum@drmartens.com +44 203 995 2644

 

Press

Maitland +44 207 379 5151

Clinton Manning +44 7711 972662

 

Gill Hammond, Director of Communications +44 7384 214248

 

This announcement contains inside information. The person responsible for arranging the release of this announcement on behalf of the Company is Emily Reichwald, Chief People and Sustainability Officer and Company Secretary.

 

About Dr. Martens

Dr. Martens is an iconic British brand founded in 1960 in Northamptonshire. Produced originally for workers looking for tough, durable boots, the brand was quickly adopted by diverse youth subcultures and associated musical movements. Dr. Martens has since transcended its working-class roots while still celebrating its proud heritage and, six decades later, "Docs" or "DM's" are worn by people around the world who use them as a symbol of empowerment and their own individual attitude. The Company is a constituent of the FTSE 250 index.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
BOAIJMLTMTABBPJ
Date   Source Headline
30th Mar 20227:00 amRNSBlock Listing Application
22nd Mar 20227:43 amRNSDirector Declaration
31st Jan 20224:23 pmRNSDirector/PDMR Shareholding
27th Jan 20227:00 amRNSTrading Statement
11th Jan 20224:11 pmRNSDirector/PDMR Shareholding
10th Jan 20225:15 pmRNSHolding(s) in Company
6th Jan 20225:30 pmRNSDr Martens
6th Jan 20227:00 amRNSResult of Secondary Placing in Dr. Martens
5th Jan 20225:12 pmRNSProposed Secondary Placing in Dr. Martens plc
13th Dec 20211:33 pmRNSChange of Auditor
9th Dec 20217:00 amRNSHalf-year Report
1st Nov 202112:53 pmRNSTotal Voting Rights
30th Sep 20218:45 amRNSBlock Listing Application
15th Sep 20217:00 amRNSDirector/PDMR Shareholding
29th Jul 20211:06 pmRNSResult of AGM
29th Jul 20217:00 amRNSTrading Statement
12th Jul 202110:00 amRNSPrior year quarterly revenue figures
1st Jul 20219:00 amRNSAnnual Financial Report
25th Jun 202112:46 pmRNSHolding(s) in Company
23rd Jun 20216:19 pmRNSHolding(s) in Company
21st Jun 202110:39 amRNSDirector/PDMR Shareholding
18th Jun 20213:16 pmRNSHolding(s) in Company
17th Jun 20217:00 amRNSFinal Results
16th Jun 20215:40 pmRNSHolding(s) in Company
13th Apr 20217:00 amRNSAppointment of Joint Corporate Brokers
10th Feb 20219:00 amRNSDirector/PDMR Shareholding
9th Feb 20211:41 pmRNSHolding(s) in Company
5th Feb 202112:52 pmRNSHolding(s) in Company
5th Feb 20219:20 amRNSExercise of Over-allotment Option
4th Feb 20215:20 pmRNSHolding(s) in Company
3rd Feb 20218:00 amRNSTotal Voting Rights
3rd Feb 20218:00 amRNSAdmission to Trading on the London Stock Exchange
1st Feb 20214:53 pmRNSDirector/PDMR Shareholding
29th Jan 202111:18 amRNSStabilisation Notice
29th Jan 202110:48 amRNSApproval and Publication of Prospectus
29th Jan 20217:00 amRNSAnnouncement of Offer Price

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.